With over 30 years of experience in the pharmaceutical industry, GP has spent the past 3 years focused on access and strategic consulting, joining Lumanity in 2024. GP’s leadership roles have encompassed serving as the lead or commercial lead for Integrated Evidence Generation Planning (IEGP) at three top 10 pharmaceutical companies – Allergan, AstraZeneca, and GSK. He has successfully embedded and supported IEGP implementation across multiple organizations and now serves as co-lead and co-creator of Lumanity’s IEGP Expert Working Group.
GP’s therapeutic expertise spans vaccines, pharmaceuticals, generics, biosimilars, and rare diseases. He has experience across central nervous system (CNS) conditions (epilepsy and migraine); gastrointestinal conditions (ulcerative colitis, Crohn’s disease, and IBS), infectious diseases (tropical medicine), respiratory conditions, and metabolic disorders (cardiovascular, diabetes, and metabolic dysfunction-associated steatohepatitis [MASH]). GP specializes in candidate selection to launch.
Before joining Lumanity, GP was the Country Manager for the UK, Ireland, and Nordics at a rare disease biotech, where he drove operational excellence and commercial growth.